Faes Farma : Q3 2021 results above expectations thanks to higher upfront payments (one-off). In-line guidance for 2021 maintained
>Q3 2021 results above expectations due to higher upfront payments (one-off) - Total revenues reached € 103m (+15% y-o-y and also above the growth of +11% in Q2 2021), with sales of traditional products in Spain maintaining a positive recovery (+5% y-o-y in Q3 2021 vs +2% in H1 2021) and also in Portugal (+19% y-o-y in Q3 2021 vs -14% H1 2021). The upturn in sales was also very strong for LatAm and exports (+67% y-o-y in Q3 2021 vs +37% in H1 2021) due to the consolid...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.